Understanding the Efficacy of CAR-T Cell Therapy for LBCL
North America: 8:00 AM (PDT)
Europe: 5:00 PM (CEST)
APAC: 2:00 PM (SGT)
CD19-targeted chimeric antigen receptor T (CAR-T) cell therapy has shown high response rates in patients with relapsed or refractory large B-cell lymphoma (LBCL) and is now approved for the treatment of adult patients who have received at least two lines of systemic therapy. However, a considerable portion of patients still fail to achieve a complete response, with durable remissions observed in less than half of treated patients. In this webinar, we present analyses from the nCounter® Analysis System, exploring characteristics of the apheresis and infusion products, as well as the tumor microenvironment, that impact outcomes of CD19 CAR-T cell therapy for patients with LBCL.
Dr. Alexandre Hirayama, MD
Research Associate, Clinical Research Division
Fred Hutchinson Cancer Research Center
Alexandre Hirayama, MD is a Research Associate in the Clinical Research Division (CRD) at the Fred Hutchinson Cancer Research Center (Fred Hutch), an Acting Instructor in the Department of Medicine at the University of Washington School of Medicine (UWSOM), and an Attending Physician at the Seattle Cancer Care Alliance (SCCA). Dr. Hirayama joined the Fred Hutch in July 2017 to train as a physician-scientist in the CRD laboratory of Cameron J. Turtle, MBBS, PhD, and has worked to elucidate factors impacting outcomes of CD19-targeted chimeric antigen receptor-modified T (CD19 CAR-T) cell therapy for patients with B-cell malignancies.